Boston, Massachusetts--(Newsfile Corp. - August 25, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.
On August 25, 2021, Bloomberg reported that shares of Cassava were down over 20% in pre-market trading "after a lawyer asked the FDA to halt the company's clinical trials of an experimental drug, citing concerns about the quality of past studies of the medicine." According to Bloomberg, a citizen petition dated August 18, 2021 "was posted on a U.S. government website Monday seeking a halt to trials of the drug Simufilam for Alzheimer's disease."
If you purchased Cassava securities, sustained substantial losses and would like more information about the investigation, or have information concerning this investigation, please visit: https://www.bermantabacco.com/case/cassava-sciences-inc/.
Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in Boston, Massachusetts and San Francisco, California.
This notice may constitute attorney advertising.
Contact:
Jay Eng, Esq.
(800) 516-9926
Email: law@bermantabacco.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94365
